| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43fe117d5e377852bbddf9b05a6702ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2021cafa8df7b0dec20ae2c7682f639 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39a39de30c45f95d7a88a72fee23a87f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d2afdc83fd18b9faa1bb20bc01ca232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba480473a6d8a5a14478f19dc3e21b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_297bfb05a11a0c1310b41f47dd769923 |
| publicationDate |
2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3893918-A1 |
| titleOfInvention |
Vasodilators for use in the treatment of a retinal ischemic disorder |
| abstract |
The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin. |
| priorityDate |
2018-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |